Abstract

This case discusses the issue of the proposed National Pharmaceutical Policy, 2006, the new drug price control policy in India. The pharma industry wants competition-based price monitoring instead of cost-based price control. However, the government is keen to add another 354 drugs to the list of drugs under price control.

Learning Objectives

The case is structured to achieve the following Learning Objectives:

• 0

Keywords

Drug Price Control Order, 1995 (DPCO, 1995), India, Pharmaceutical Industry, unbranded generic drugs, trade margins, wholesalers, retailers, competition-based price monitoring, National List of Essential Medicines, Union minister for Chemicals and Fertilizers, Ram Vilas Paswan, National Pharmaceutical Policy 2006